Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabiae in Patients with Relapsed/Refractory AML

被引：0
|
作者：
Schimmer, Aaron D. [1 ]
Estey, Elihu H. [7 ]
Borthakur, Gautam [7 ]
Carter, Bing [7 ]
Schiller, Gary J. [2 ]
Tallman, Martin S. [3 ]
Altman, Jessica K. [3 ]
Karp, Judith E. [4 ]
Kassis, Jeannine [5 ]
Jacob, Christine [6 ]
Morris, Stephen [6 ]
Jolivet, Jacques [6 ]
Andreeff, Michael [7 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada
[6] Aegera Therapeut Inc, Montreal, PQ, Canada
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：283 / 284
页数：2
相关论文
共 50 条
  • [41] Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML
    Fiedler, Walter
    Heuser, Michael
    Chromik, Joerg
    Thol, Felicitas
    Bokemeyer, Carsten
    Theile, Susann
    Lebkuechner, Isabell
    Kranich, Anne L.
    BLOOD, 2016, 128 (22)
  • [42] Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
    Hijiya, Nobuko
    Thomson, Blythe
    Isakoff, Michael S.
    Silverman, Lewis B.
    Steinherz, Peter G.
    Borowitz, Michael J.
    Kadota, Richard
    Cooper, Todd
    Shen, Violet
    Dahl, Gary
    Thottassery, Jaideep V.
    Jeha, Sima
    Maloney, Kelly
    Paul, Jo-Anne
    Barry, Elly
    Carroll, William L.
    Gaynon, Paul S.
    BLOOD, 2011, 118 (23) : 6043 - 6049
  • [43] Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Badros, A
    Goloubeva, O
    Rapoport, AP
    Ratterree, B
    Gahres, N
    Meisenberg, B
    Takebe, N
    Heyman, M
    Zwiebel, J
    Streicher, H
    Gocke, CD
    Tomic, D
    Flaws, JA
    Zhang, B
    Fenton, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4089 - 4099
  • [44] Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
    Miller, Timothy
    Cudkowicz, Merit
    Shaw, Pamela J.
    Andersen, Peter M.
    Atassi, Nazem
    Bucelli, Robert C.
    Genge, Angela
    Glass, Jonathan
    Ladha, Shafeeq
    Ludolph, Albert L.
    Maragakis, Nicholas J.
    McDermott, Christopher J.
    Pestronk, Alan
    Ravits, John
    Salachas, Francois
    Trudell, Randall
    Van Damme, Philip
    Zinman, Lorne
    Bennett, C. Frank
    Lane, Roger
    Sandrock, Alfred
    Runz, Heiko
    Graham, Danielle
    Houshyar, Hani
    McCampbell, Alexander
    Nestorov, Ivan
    Chang, Ih
    McNeill, Manjit
    Fanning, Laura
    Fradette, Stephanie
    Ferguson, Toby A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02): : 109 - 119
  • [45] Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Htut, Myo
    Gasparetto, Cristina
    Zonder, Jeffrey A.
    Martin, Thomas G., III
    Chen, Janice
    Brooks, Christopher
    McDonald, Peter
    Rupprecht, Nicole
    Wysowskyj, Halyna
    Chauhan, Dharminder
    Ray, Arghya
    Anderson, Kenneth C.
    Paba-Prada, Claudia E.
    BLOOD, 2019, 134
  • [46] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Cooper, Brenda
    Elson, Paul
    Mukherjee, Sudipto
    Fensterl, Jaime
    Gerds, Aaron T.
    Caimi, Paolo F.
    Tomlinson, Ben K.
    Malek, Ehsan
    Little, Jane A.
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Kane, Donna
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Bevier, Barbara
    Goebel, Christopher
    Zimmerman, Cassie
    Nielsen, Alek D.
    Hirsch, Cassandra M.
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    deLima, Marcos
    Jacobberger, James
    Woost, Philip
    Sekeres, Mikkael A.
    BLOOD, 2016, 128 (22)
  • [47] A Phase II Trial of Chloroquine in Combination with Bortezomib and Cyclophosphamide in Patients with Relapsed and Refractory Multiple Myeloma
    Montanari, Francesca
    Lu, Meina
    Marcus, Sara
    Saran, Ankeeta
    Malankar, Aditya
    Mazumder, Amitabha
    BLOOD, 2014, 124 (21)
  • [48] A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Maly, Joseph J.
    Christian, Beth A.
    Zhu, Xiaohua
    Wei, Lai
    Sexton, Jennifer L.
    Jaglowski, Samantha M.
    Devine, Steven M.
    Fehniger, Todd A.
    Wagner-Johnston, Nina D.
    Phelps, Mitch A.
    Bartlett, Nancy L.
    Blum, Kristie A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (06): : 347 - 353
  • [49] PRELIMINARY PHASE II RESULTS OF ARA-C AND IDARUBICIN IN COMBINATION WITH SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND SELINEXOR (KPT-330) IN PATIENTS WITH RELAPSED OR REFRACTORY AML
    Fiedler, W.
    Heuser, M.
    Ottmann, O.
    Kebenko, M.
    Thol, F.
    Trummer, A.
    Brandts, C.
    Bokemeyer, C.
    Theile, S.
    Kranich, A.
    HAEMATOLOGICA, 2015, 100 : 221 - 221
  • [50] A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Walker, Alison R.
    Vasu, Sumithra
    Mims, Alice S.
    Walsh, Katherine J.
    Behbehani, Gregory K.
    Blachly, James S.
    Vittorio, Molly
    Zhao, Qiuhong
    Ruppert, Amy S.
    Orwick, Shelley
    Ranganathan, Parvathi
    Byrd, John C.
    Blum, William
    Garzon, Ramiro
    BLOOD, 2016, 128 (22)
12345